Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AnGes MG Resumes Development of NF-κB Decoy Oligo Ointment Formulation for Atomic Dermatitis
August 26, 2014
- Chugai to Restrict Use of Alecensa to Medical Institutions, Doctors that Meet Specified Conditions
August 26, 2014
- AnGes MG Revamps US Unit to Prepare for Global PIII Study of Collategene
August 25, 2014
- Janssen Files Anti-HIV Combination Tablet for Approval
August 25, 2014
- Latuda Goes on Sale in UK: Sumitomo Dainippon
August 25, 2014
- Pfizer Japan to Create New Unit for its Innovative Drug Business in December
August 22, 2014
- Nichi-Iko to Launch Own Products in Thailand in October
August 22, 2014
- Carfilzomib Monotherapy Fails to Meet Primary Endpoint in PIII: Amgen, Onyx
August 22, 2014
- MTPC, AZ Ink Research Collaboration Deal in Diabetic Nephropathy
August 21, 2014
- Eisai Files Fycompa for Primary Generalized Tonic-Clonic Seizures in US, Europe
August 21, 2014
- Japan to See Grueling Battle for Free-Price Viagra Generics
August 20, 2014
- Launch of Daiichi Sankyo Espha’s Cravit Generics Not Yet Determined
August 20, 2014
- Daiichi Sankyo Starts PIII Study of Etanercept Biosimilar, Eying Approval in FY2016
August 20, 2014
- Approval Conditions Lifted for Tykerb: GSK
August 20, 2014
- Pfizer Reveals First Doctor Payments amid Delays in Disclosure
August 19, 2014
- Eisai Licenses Pariet Successor to Zeria
August 19, 2014
- Eisai Files for Regulatory Approval of Lenvatinib in US, Europe
August 19, 2014
- Announcement: Sales Excellence Japan 2014 to Be Held on October 14, 15
August 18, 2014
- Genzyme Japan Appoints Former Bausch & Lomb Japan President Ashikaga as Its New President
August 18, 2014
- Teva Receives Marketing Authorization for 4 APIs/9 Products
August 18, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…